Gene therapy for cystic fibrosis: 15-Year safety watch begins
NCT ID NCT06962852
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 21 times
Summary
This study follows 5 people with cystic fibrosis who received a single dose of BI 3720931 gene therapy in an earlier trial. Participants do not receive any new treatment. Doctors will check their health and lung function for up to 15 years to see if the therapy remains safe and effective over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hôpital Gui de Chauliac
Montpellier, 34295, France
-
Osp. Pediatrico Bambin Gesù
Roma, 00165, Italy
-
Royal Brompton Hospital
London, SW3 6JY, United Kingdom
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
Conditions
Explore the condition pages connected to this study.